EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCBB: “BIEI”) a biopharmaceutical company focused on developing and commercializing innovative immune system manipulation therapies for breast cancer, Alzheimer’s disease, multiple sclerosis (MS), traumatic brain injury (TBI), and others today announced that the United States Patent Office approved a patent on their proprietary medication “Feldetrex ™”, which is designed to relieve the symptoms of neuropathic pain and fibromyalgia. The William Beaumont Army Medical Center Principal Investigator is drafting a protocol to conduct a double-blind, placebo-controlled comparison of this medication and the leading FDA-approved regimen for these concerns and will be submitting it for IRB approval in the near future.
Help employers find you! Check out all the jobs and post your resume.
